Aethlon Medical Inc, a pioneer in blood purification technology, presents its corporate outlook in this detailed presentation.
The Hemopurifier® by Aethlon demonstrates promising results in clearing enveloped viruses and extracellular vesicles in early clinical trials, offering new hope in treating life-threatening conditions.
With two FDA 'Breakthrough Device' designations, Aethlon's Hemopurifier® targets therapeutic pathways in oncology and infectious diseases, with active research in Long COVID and a strong patent portfolio for competitive advantage.
Patented Technology
The Aethlon Hemopurifier® showcases a proprietary and patented design for blood purification, proven in early trials to clear viruses and extracellular vesicles efficiently.
Clinical Success
167 Hemopurifier sessions across 41 patients display a favorable safety profile, supporting the potential of Hemopurifier® in clearing tumor-derived EVs and associated cargo.
Strategic Focus
Aethlon's focus on oncology and infectious diseases, combined with FDA designations, positions the Hemopurifier® as a versatile solution for high-value therapeutic areas.
- Aethlon's Hemopurifier® shows promising results in clearing enveloped viruses and extracellular vesicles, offering a new approach in treating life-threatening conditions.
- The advanced technology targets therapeutic pathways in oncology and infectious diseases, with potential expansion opportunities across various medical fields.
Aethlon Medical Inc's groundbreaking approach with the Hemopurifier® presents a potential game-changer in blood purification technology, offering hope for patients facing challenging medical conditions. With a strong focus on innovation and clinical success, Aethlon is poised for significant growth and impact in the healthcare industry.